ATOSSA THERAPEUTICS, INC. - FORM S-1/A - EX-99.6 - EXHIBIT 99.6 - April 23, 2018

Attached files

file filename
EX-99.7 - EXHIBIT 99.7 - ATOSSA THERAPEUTICS, INC.s109744_ex99-7.htm
EX-99.5 - EXHIBIT 99.5 - ATOSSA THERAPEUTICS, INC.s109744_ex99-5.htm
EX-99.4 - EXHIBIT 99.4 - ATOSSA THERAPEUTICS, INC.s109744_ex99-4.htm
EX-99.3 - EXHIBIT 99.3 - ATOSSA THERAPEUTICS, INC.s109744_ex99-3.htm
EX-99.2 - EXHIBIT 99.2 - ATOSSA THERAPEUTICS, INC.s109744_ex99-2.htm
EX-99.1 - EXHIBIT 99.1 - ATOSSA THERAPEUTICS, INC.s109744_ex99-1.htm
EX-23.1 - EXHIBIT 23.1 - ATOSSA THERAPEUTICS, INC.s109744_ex23-1.htm
EX-8.1 - EXHIBIT 8.1 - ATOSSA THERAPEUTICS, INC.s109744_ex8-1.htm
EX-5.1 - EXHIBIT 5.1 - ATOSSA THERAPEUTICS, INC.s109744_ex5-1.htm
EX-4.4 - EXHIBIT 4.4 - ATOSSA THERAPEUTICS, INC.s109744_ex4-4.htm
EX-4.3 - EXHIBIT 4.3 - ATOSSA THERAPEUTICS, INC.s109744_ex4-3.htm
EX-4.2 - EXHIBIT 4.2 - ATOSSA THERAPEUTICS, INC.s109744_ex4-2.htm
EX-4.1 - EXHIBIT 4.1 - ATOSSA THERAPEUTICS, INC.s109744_ex4-1.htm
EX-1.1 - EXHIBIT 1.1 - ATOSSA THERAPEUTICS, INC.s109744_ex1-1.htm
S-1/A - FORM S-1 - ATOSSA THERAPEUTICS, INC.s109744_s-1.htm

 

Exhibit 99.6

 

FORM OF

NOMINEE HOLDER CERTIFICATION

ATOSSA GENETICS INC.

 

The undersigned, a bank, broker, dealer, trustee, depositary, or other nominee of non-transferable subscription rights to purchase units of Atossa Genetics Inc. (the “Company”), said units each comprised of one share of Series B Convertible Preferred Stock and 284 warrants pursuant to the subscription rights offering described and provided for in the Company’s prospectus dated [______], 2018, hereby certifies to the Company and Broadridge Corporate Issuer Solutions, Inc., as subscription agent for such rights offering, that (1) the undersigned has exercised, on behalf of the beneficial owners thereof (which may include the undersigned), the number of subscription rights on the terms and subject to the conditions set forth in the prospectus specified below pursuant to the basic subscription right (as defined in the prospectus) and, on behalf of beneficial owners of subscription rights who have subscribed for the purchase of additional units pursuant to the over-subscription privilege (as defined in the prospectus), the number of units specified below, listing separately below each such exercised basic subscription right and the corresponding over-subscription privilege (without identifying any such beneficial owner), and (2) to the extent a beneficial owner has elected to subscribe for units pursuant to the over-subscription privilege, each such beneficial owner’s basic subscription right has been exercised in full:

 

Number of Shares
Owned
on the Record Date

  

Individual
Soliciting
Broker
(if any)

  

Number of Units Subscribed for
Pursuant to the
Basic Subscription Right

  

Number of Units Subscribed for
Pursuant to the
Over-Subscription Privilege

1.            
       
2.            
       
3.            
       
4.            
       
5.            
       
6.            
       
7.            

 

Name of Nominee Holder
     
By:    
     
Name:    
     
Title:    
     
Phone Number:    
     
Fax Number:    
     
Dated:    
     

 

Provide the following information, if applicable:
     

DTC Participant Number

 

 

 

DTC Participant    
     
By:    
     
Name:    
     
Title:    
     
DTC Basic Subscription
Confirmation Number(s)
     
Dated:    

 

 

 

ATOSSA THERAPEUTICS, INC. Reports